Navigation Links
Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
Date:11/26/2007

PITTSBURGH, Nov. 26 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Steven G. Zylstra as Vice President, Global Corporate Communication and Public Relations. Mr. Zylstra will manage and oversee all internal and external communications and provide communications and public relations counsel to members of Mylan's global senior management team in their various roles across the Company.

Mr. Zylstra joins Mylan from the Pittsburgh Technology Council and the Pittsburgh Biomedical Development Corporation where he served as President and CEO. He joined the Pittsburgh Technology Council et al after serving as Director, Business Development, for Simula Technologies Inc. Prior to joining Simula, Mr. Zylstra served as General Manager, General Pneumatics Corporation's Western Research Center, and, prior to that, he served as Technical Manager for Bendix Guidance Systems Division. Mr. Zylstra joins Mylan with nearly 30 years of public relations, senior management, business development, marketing, government relations and engineering experience, including the past seven years as a chief spokesman for the technology and manufacturing industries in southwestern Pennsylvania.

Mylan Vice Chairman and CEO Robert J. Coury said: "In Steve, Mylan is adding yet another highly-seasoned, top-notch leader to further strengthen our senior management team. His rich and diverse background steeped in technology and manufacturing, makes him especially well suited to articulate the dynamic future and intrinsic complexities of both Mylan and of the generic and specialty pharmaceuticals industries."

Mr. Zylstra said: "I am elated to be joining Mylan at this transformational period in the Company's already prosperous history. I look forward to working with the members of an extraordinary global management team and supporting them and their operations with a world-class communications program as Mylan becomes the leading quality generic and specialty pharmaceutical company in the world."

Mr. Zylstra earned a bachelor's of science degree from Western Michigan University.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , This report ... technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used ... on biomarker. Currently the most important applications of biomarkers ...
(Date:12/5/2016)... , Dec. 5, 2016 /PRNewswire/ - Resverlogix ...  that the independent Data and Safety Monitoring Board ... in high-risk cardiovascular disease (CVD) patients has completed ... the study should continue as planned without any ... noted that no safety or efficacy concerns were ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed ... businesses in federally funded research and development is welcome news for the photonics ... photonics . , As part of the National Defense Authorization Act (NDAA) compromise ...
(Date:12/2/2016)... Dec. 2, 2016 More than $4.3 million was ... Medals dinner ( DHMD ). The gala was held at the ... York City and honored Alan Alda ... to health and medicine and the public understanding of science. ... 2006, the event has raised $40 million for the Laboratory,s ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
Breaking Biology News(10 mins):